GeoVax Reports Q2 GAAP EPS Loss of -$0.97, Beats Estimates
In its second-quarter financial report for 2025, GeoVax (NASDAQ: GOVX) reported a GAAP earnings per share loss of $0.97, which exceeded analyst expectations by $1.18. Despite the negative EPS result, the company's performance was better than anticipated due to government contract revenues from its agreement with the Biomedical Advanced Research and Development Authority. For both the three-month period ending June 30, 2025, and the six-month period through the same date, GeoVax generated $852,282 and $2,489,145 in government contract revenues respectively. These figures highlight ongoing support from federal contracts, which may provide a stabilizing influence amid financial challenges. The results reflect continued operational losses but underscore sustained revenue inflows that could help the company maintain operations while advancing its development pipeline.
Topics: biotech government_contract_revenue